血管紧张素转换酶抑制剂类药物治疗原发性高血压的成本-效果分析  

Five Angiotensin Converting Enzyme Inhibitors for Essential Hypertension:Cost-Effectiveness Analysis

作　　者：王家伟[1] 张成[1] 

机构地区：[1]首都医科大学附属北京同仁医院,北京市100730

出　　处：《中国药房》2008年第14期1044-1045,共2页China Pharmacy

摘　　要：目的:分析不同血管紧张素转换酶抑制剂治疗原发性高血压的经济学效果。方法:将符合原发性高血压诊断标准的门诊患者120例随机分为A、B、C、D、E组,分别给予国产卡托普利、合资卡托普利、福辛普利钠、盐酸贝那普利、马来酸依那普利治疗,疗程均为4周,运用成本-效果分析法进行评价。结果:A、B、C、D、E组总有效率分别为75.00%、75.00%、91.67%、91.67%、87.50%;C、D、E组相对于A组的增量成本-效果比分别为1249.67、1256.39、636.16。结论:E组虽然总有效率略低于C、D组,但成本-效果比及增量成本-效果比均较低,不良反应较少,为较佳治疗方案。OBJECTIVE： To evaluate the cost - effectiveness of 5 angiotensin converting enzyme inhibitors in the treatment of essential hypertension. METHODS： 120 patients with essential hypertension were randomly assigned to receive domestic captopril （Group A）, captopril from joint venture （Group B）, fosinopril （Group C）, benazepril （Group D） or enalapril （Group E） for 4 weeks. The cost- effectiveness of the 5 groups was evaluated. RESULTS： The total effective rates for A, B, C, D and E groups were 75.00%, 75.00%, 91.67%, 91.67% and 87.50%, respectively. As compared with Group A, the incremental cost- effectiveness ratios of C, D and E groups were 1 249.67, 1 256.39 and 636.16, respectively. CONCLUSION： The total effective rate in Group E is slightly less than in other groups, yet Group E is superior to other groups because of its lower cost - effectiveness ratio and lower incremental cost - effectiveness ratio.

关 键 词：原发性高血压 卡托普利 福辛普利 贝那普利 马来酸依那普利 成本-效果分析 

分 类 号：R972.4[医药卫生—药品] R956[医药卫生—药学]